|
|
|
|
| LEADER |
00000nab a2200000 i 4500 |
| 001 |
publ2378 |
| 005 |
20250307115549.0 |
| 008 |
250307s2005 hu o 0|| Angol d |
| 022 |
|
|
|a 0361-9230
|
| 024 |
7 |
|
|a 10.1016/j.brainresbull.2005.03.012
|2 doi
|
| 024 |
7 |
|
|a 2802858
|2 mtmt
|
| 040 |
|
|
|a PPKE Publikáció Repozitórium
|b hun
|
| 041 |
|
|
|a Angol
|
| 100 |
1 |
|
|a Erdő Franciska
|
| 245 |
1 |
4 |
|a The AMPA-antagonist talampanel is neuroprotective in rodent models of focal cerebral ischemia.
|h [elektronikus dokumentum] /
|c Erdő Franciska
|
| 260 |
|
|
|c 2005
|
| 300 |
|
|
|a 43-49
|
| 490 |
0 |
|
|a BRAIN RESEARCH BULLETIN
|v 66 No. 1
|
| 520 |
3 |
|
|a Cerebroprotection after administration of glutamate receptor antagonists has been well documented. The present study is intended to determine whether the non-competitive alpha-amino-3-hydroxy-methyl-4-isoxazolyl-propionic acid (AMPA) receptor antagonist talampanel, known as antiepileptic drug, has neuroprotective effects in stroke models in rodents. The infarct size was measured in three models of stroke by 2,3,5-triphenyltetrazolium chloride staining. Therapeutic time window was also examined in rats subjected to 1h middle cerebral artery occlusion. The degree of neuroprotection was tested in mice, using 1.5, 2 h or permanent middle cerebral artery occlusions. Effect on photochemically induced thrombosis was investigated in rats applying 30 min time window after brain irradiation. Talampanel reduced the infarct size by 47.3% (p<0.01) after a 30 min delay and 48.5% (p<0.01) after 2 h delay following middle cerebral artery occlusion in rats. In mice, talampanel reduced the extension of the infarcted tissue at the levels of striatum and hippocampus by 44.5% (p<0.05) and 39.3% (p<0.01) after 1.5 h transient ischemia and still caused 37.0% (p<0.05) and 37.0% (p<0.05) inhibitions when 2 h occlusion was applied. In photothrombosis talampanel showed a 40.1% (p<0.05) inhibition. Protective actions of talampanel in various stroke models, in rats and mice, suggest a possible therapeutic role of the compound in stroke patients.
|
| 650 |
|
4 |
|a Idegtudományok (benne pszichofiziológia)
|
| 700 |
0 |
1 |
|a Berzsenyi P
|e aut
|
| 700 |
0 |
1 |
|a Andrasi F
|e aut
|
| 856 |
4 |
0 |
|u https://publikacio.ppke.hu/id/eprint/2378/1/brainresearchbulletin2005.pdf
|z Dokumentum-elérés
|